SG11201906682YA - Glucagon receptor binding proteins and methods of use thereof - Google Patents

Glucagon receptor binding proteins and methods of use thereof

Info

Publication number
SG11201906682YA
SG11201906682YA SG11201906682YA SG11201906682YA SG11201906682YA SG 11201906682Y A SG11201906682Y A SG 11201906682YA SG 11201906682Y A SG11201906682Y A SG 11201906682YA SG 11201906682Y A SG11201906682Y A SG 11201906682YA SG 11201906682Y A SG11201906682Y A SG 11201906682YA
Authority
SG
Singapore
Prior art keywords
international
south san
san francisco
pct
binding proteins
Prior art date
Application number
SG11201906682YA
Inventor
Wenyan Shen
Yan Wang
Hugo Matern
Zhonghao Liu
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of SG11201906682YA publication Critical patent/SG11201906682YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

a 600 • -•500 .-! DOX 0 1 2 3 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 August 2018 (02.08.2018) WIP0 I PCT Hu onus °nolo olomonliomioluo ow (10) International Publication Number WO 2018/140729 Al (51) International Patent Classification: A61K 39/00 (2006.01) C07K 16/00 (2006.01) A61K 39/395 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2018/015452 (22) International Filing Date: 26 January 2018 (26.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/451,603 27 January 2017 (27.01.2017) US (71) Applicant: NGM BIOPHARMACEUTICALS, INC. [US/US]; 333 Oyster Point Blvd, South San Francisco, CA 94080 (US). (72) Inventors: SHEN, Wenyan; 333 Oyster Point Blvd, South San Francisco, CA 94080 (US). WANG, Yan; 333 Oys- ter Point Blvd, South San Francisco, CA 94080 (US). MATERN, Hugo; 333 Oyster Point Blvd, South San Fran- cisco, CA 94080 (US). LIU, Zhonghao; 333 Oyster Point Blvd, South San Francisco, CA 94080 (US). (74) Agent: WEISSER, Tamera, M. et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — (54) Title: GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE THEREOF Fed Blood Glucose N O Weeks Post mAb Dosing FIG. 3 anti-KLH --or-3H5 3 6B5 -x .5B11 1-1 N (57) : The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use. [Continued on next page] C WO 2018/140729 Al MIDEDIMOMMIDIREEMOMOEMOIRMIHOMODEVOIMIE Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11201906682YA 2017-01-27 2018-01-26 Glucagon receptor binding proteins and methods of use thereof SG11201906682YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762451603P 2017-01-27 2017-01-27
PCT/US2018/015452 WO2018140729A1 (en) 2017-01-27 2018-01-26 Glucagon receptor binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201906682YA true SG11201906682YA (en) 2019-08-27

Family

ID=62979257

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906682YA SG11201906682YA (en) 2017-01-27 2018-01-26 Glucagon receptor binding proteins and methods of use thereof

Country Status (17)

Country Link
US (3) US10995145B2 (en)
EP (1) EP3573651A4 (en)
JP (1) JP7005638B2 (en)
KR (1) KR102627311B1 (en)
CN (1) CN110520151B (en)
AU (1) AU2018213374A1 (en)
BR (1) BR112019015479A2 (en)
CA (1) CA3048913A1 (en)
CL (1) CL2019002081A1 (en)
CO (1) CO2019009035A2 (en)
IL (1) IL267638A (en)
MX (1) MX2019008722A (en)
PE (1) PE20191404A1 (en)
PH (1) PH12019501605A1 (en)
RU (1) RU2019126781A (en)
SG (1) SG11201906682YA (en)
WO (1) WO2018140729A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102627311B1 (en) 2017-01-27 2024-01-22 엔지엠 바이오파마슈티컬스, 아이엔씨. Glucagon receptor binding protein and methods of use thereof
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
AU2019410643A1 (en) 2018-12-21 2021-08-12 Jiangsu Hengrui Medicine Co., Ltd. Bispecific protein
WO2022083720A1 (en) * 2020-10-23 2022-04-28 江苏恒瑞医药股份有限公司 Glp1-gcgr antibody fusion protein variant and composition comprising same
KR20230004135A (en) * 2021-06-30 2023-01-06 한미약품 주식회사 Therapeutic use of a combination comprising a trigonal glucagon/GLP-1/GIP receptor agonist

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK580789D0 (en) 1989-11-20 1989-11-20 Novo Nordisk As PROCEDURE FOR PURIFICATION OF POLYPEPTIDES
DE69333726T8 (en) 1992-08-28 2006-04-27 Novo Nordisk A/S glucagon
US5776725A (en) 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
US20040037826A1 (en) 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
CL2007002668A1 (en) 2006-09-20 2008-05-09 Amgen Inc ANTIGEN UNION PROTEIN THAT JOINS THE HUMAN GLUCAGON RECEIVER; NUCLEIC ACID THAT CODIFIES IT; METHOD OF PRODUCTION; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT OR PREVENT TYPE 2 DIABETES.
PE20140132A1 (en) 2007-09-26 2014-02-14 Chugai Pharmaceutical Co Ltd IL-6 ANTI-RECEPTOR ANTIBODY
US7736648B2 (en) 2007-10-25 2010-06-15 Trellis Bioscience, Inc. Anti-RSV G protein antibodies
PE20091674A1 (en) 2008-03-27 2009-11-04 Lilly Co Eli GLUCAGON RECEPTOR ANTAGONISTS
CA2742157A1 (en) 2008-10-31 2010-05-06 Toray Industries, Inc. Immunoassay method for human cxcl1 protein
EP2475683A4 (en) * 2009-09-08 2013-04-24 Neopharm Co Ltd Antibodies against glucagon receptor and their use
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
JO3756B1 (en) 2010-11-23 2021-01-31 Regeneron Pharma Human antibodies to the glucagon receptor
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
US9934913B2 (en) 2011-10-26 2018-04-03 Nokia Technologies Oy Apparatus and associated methods
US20140275368A1 (en) 2013-03-14 2014-09-18 Sabic Innovative Plastics Ip B.V. Blended polymer compositions with improved mold release properties
MX2015015339A (en) 2013-05-07 2016-07-15 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof.
CN104231083A (en) * 2013-06-09 2014-12-24 杭州鸿运华宁生物医药工程有限公司 Antibody for resisting to glucagon receptor and use thereof
CN106459971B (en) 2014-04-08 2019-08-16 弗劳恩霍夫应用研究促进协会 For treating the conjoint therapy of autoimmune disease
CN108025060A (en) 2014-06-08 2018-05-11 瑞美德生物医药科技有限公司 Use the method for glucagon receptor antagonistic antibodies treatment type 1 diabetes
SG11201701711VA (en) 2014-09-16 2017-04-27 Regeneron Pharma Anti-glucagon antibodies and uses thereof
AU2016242935B2 (en) 2015-04-02 2020-10-01 Remd Biotherapeutics, Inc. Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies
CN108348582B (en) 2015-09-04 2023-04-14 瑞美德生物医药科技有限公司 Methods for treating heart failure using glucagon receptor antagonist antibodies
US20190062441A1 (en) 2015-10-07 2019-02-28 Remd Biotherapeutics, Inc. Methods For Treating Rare Genetic Disorders Using Glucagon Receptor Antagonistic Antibodies
US20190002577A1 (en) 2016-01-04 2019-01-03 Remd Biotherapeutics, Inc. Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
KR102627311B1 (en) 2017-01-27 2024-01-22 엔지엠 바이오파마슈티컬스, 아이엔씨. Glucagon receptor binding protein and methods of use thereof
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent

Also Published As

Publication number Publication date
PE20191404A1 (en) 2019-10-04
US20240084023A1 (en) 2024-03-14
US10995145B2 (en) 2021-05-04
RU2019126781A3 (en) 2021-10-27
RU2019126781A (en) 2021-03-01
CA3048913A1 (en) 2018-08-02
PH12019501605A1 (en) 2020-06-01
AU2018213374A1 (en) 2019-07-11
EP3573651A1 (en) 2019-12-04
US20180273629A1 (en) 2018-09-27
CO2019009035A2 (en) 2020-01-17
JP7005638B2 (en) 2022-02-04
KR20190113815A (en) 2019-10-08
CL2019002081A1 (en) 2019-12-20
EP3573651A4 (en) 2020-10-14
US20210332144A1 (en) 2021-10-28
MX2019008722A (en) 2019-10-02
US11732049B2 (en) 2023-08-22
CN110520151B (en) 2024-04-12
CN110520151A (en) 2019-11-29
IL267638A (en) 2019-08-29
WO2018140729A1 (en) 2018-08-02
BR112019015479A2 (en) 2020-03-31
JP2020506692A (en) 2020-03-05
KR102627311B1 (en) 2024-01-22

Similar Documents

Publication Publication Date Title
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201901126UA (en) Combination therapy for cancer
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201906682YA (en) Glucagon receptor binding proteins and methods of use thereof
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201907580SA (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201908092RA (en) Anti-tigit antigen-binding proteins and methods of use thereof
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201909561RA (en) Octree-based convolutional neural network
SG11201803676PA (en) Site specific her2 antibody drug conjugates